<DOC>
	<DOC>NCT00296530</DOC>
	<brief_summary>This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.</brief_summary>
	<brief_title>Study Of Patients With Allergic Rhinitis And Asthma</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUSÂ® 100/50mcg BID or Placebo BID</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Have asthma for at least 3 months prior to the study. Have been using an allowed prestudy asthma therapy for at least 3 months prior to study. Currently have seasonal allergic rhinitis and have had seasonal onset of allergic rhinitis for at least the two previous allergy seasons. Have a positive allergy skin test. Have a history of lifethreatening asthma. Been hospitalized for asthma within the 6 months prior to the study. Have certain conditions that would make study participation unsafe. The study doctor will evaluate other inclusion and exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic Rhinitis</keyword>
</DOC>